Israel Biotech Fund News
5 articles
growth-positive
חברת תרופות בינלאומית תשתף פעולה עם קרן הון סיכון ישראלית
Pharmaceutical company, לונזה, has entered into a unique partnership with Israeli venture capital fund, Israel Biotech Fund (IBF). Under the agreement, לונזה will provide development and manufacturing services for companies in IBFs portfolio, while IBF will help לונזה penetrate the Israeli market. The partnership is expected to accelerate drug development in Israel and reduce risk for לונזה. The companies believe that the collaboration will benefit both parties and lead to innovative business models. Additionally, דן טלמן will join IBF as a partner, bringing his expertise in product development and fundraising.
Partners
growth-positive
Israel Biotech Fund closes $112m second fund
Israel Biotech Fund (IBF) has closed its $112 million second fund, which is larger than its first fund. The main investors in the second fund include Harel Insurance Investments and Financial Services Ltd., Bristol Myers Squibb (BMS), and CBG Capital. IBF focuses on investments in drug development and medical diagnostics companies. Some of IBFs portfolio companies have achieved major milestones, such as Biond Biologics selling the rights to its lead product for treating cancer to Sanofi for a first payment of $125 million. IBF has also partnered with Clal Biotechnology Industries Ltd. to set up a special purpose acquisition company (SPAC) to merge with an Israeli life sciences company. IBF has won the Israel Innovation Authority tender to set up an AI pharma laboratory with partners Pfizer, Astrazeneca, Merck, Teva, and Amazon.
InvestmentPartners
growth-positive
Israel Biotech Fund reports first closure of 2nd fund
Israel Biotech Fund (IBF) has announced the first closure for its second fund, with the volume and extent undisclosed. IBF was founded in 2015 and has a team of over 25 venture advisors. The portfolio companies of IBFs first fund include Ayala Pharmaceuticals, Pharm Two B, and Biond Biologics. The appointment of venture advisors as directors and advisors for the funds portfolio companies is expected to bring significant changes. The global pharma and biotech industry has been undergoing major changes, resulting in an increase in the number of new drugs approved by the FDA. Israels biotech industry is also showing impressive progress. Prominent investors in IBFs fund include Consensus Business Group (CBG).
Investment
growth-positive
Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector
The article discusses the growth and development of Israels biotech sector, with a focus on the role of OrbiMed as an investor. OrbiMed has helped invigorate the sector and bridge the gap between preclinical and clinical development. The article highlights OrbiMeds investment in 89bio, a biotech company focused on developing a drug for nonalcoholic steatohepatitis (NASH). It also mentions Compugen, another Israeli company that has transitioned to clinical trials and formed partnerships with major pharmaceutical companies. The Israel Biotech Fund is also mentioned as a contributor to the growth of the Israeli biotech industry. Overall, the article emphasizes the positive growth and potential of Israels biotech sector.
InvestmentExpand
growth-positive
Israel Biotech Fund begins investing $100m
Israel Biotech Fund has selected cancer drug developer Vidac for its first investment. The $100 million fund, managed by Prof. David Sidransky, Ido Zairi, and Dr. Yuval Cabilly, is backed by investors including Biogen, Medison, and an anonymous pharmaceutical company. The fund aims to invest in 8-10 companies and provide consultation to others in the Israeli biotech industry. The founders of the fund have been helping Israeli biotech startups for years and want to establish at least one major Israeli international biotech company. The focus is on supporting companies to reach later stages of clinical trials and obtain suitable budgets.
Investment
